Risks of Ventricular Arrhythmia and Heart Failure in Carriers of RBM20 Variants
Circulation: Genomic and Precision Medicine · 2023-10 · 16 (5) · 434-441
DOI: 10.1161/circgen.123.004059 ↗Kurz gefasst
Fachartikel in der Zeitschrift Circulation: Genomic and Precision Medicine, 2023-10. Verfasst von Douglas E Cannie und 33 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Cardiovascular Science, University College London, United Kingdom (D.E.C., A.P., A.B., P.S., M.L., P.M.E.). Hauptthemen laut MEDLINE: Heart Failure, Ventricular Dysfunction, Left. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
BACKGROUND: Variants in RBM20 are reported in 2% to 6% of familial cases of dilated cardiomyopathy and may be associated with fatal ventricular arrhythmia and rapid heart failure progression. We sought to determine the risk of adverse events in RBM20 variant carriers and the impact of sex on outcomes. METHODS: Consecutive probands and relatives carrying RBM20 variants were retrospectively recruited from 12 cardiomyopathy units. The primary end point was a composite of malignant ventricular arrhythmia (MVA) and end-stage heart failure (ESHF). MVA and ESHF end points were also analyzed separately and men and women compared. Left ventricular ejection fraction (LVEF) contemporary to MVA was examined. RBM20 variant carriers with left ventricular systolic dysfunction ( RBM20 LVSD ) were compared with variant-elusive patients with idiopathic left ventricular systolic dysfunction. RESULTS: Longitudinal follow-up data were available for 143 RBM20 variant carriers (71 men; median age, 35.5 years); 7 of 143 had an MVA event at baseline. Thirty of 136 without baseline MVA (22.0%) reached the primary end point, and 16 of 136 (11.8%) had new MVA with no significant difference between men and women (log-rank P =0.07 and P =0.98, respectively). Twenty of 143 (14.0%) developed ESHF (17 men and 3 women; log-rank P 35%. At 5 years, 15 of 67 (22.4%) RBM20 LVSD versus 7 of 197 (3.6%) patients with idiopathic left ventricular systolic dysfunction had reached the primary end point (log-rank P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Cardiovascular Science, University College London, United Kingdom (D.E.C., A.P., A.B., P.S., M.L., P.M.E.).
- Department of Inherited Cardiovascular Diseases, Barts Heart Centre, St Bartholomew's Hospital, London, United Kingdom (D.E.C., A.P., A.B., M.L., P.M.E.).
- Population, Policy and Practice Research and Teaching Department, UCL Great Ormond Street Institute of Child Health, United Kingdom (B.D.S.).
- Department of Cardiology, Aarhus University Hospital, Denmark (L.B., A.M.D., T.B.R.).
- Department of Cardiology, Odense University Hospital, Denmark (T.M.H., F.G.H.).
- Inherited Cardiac Disease Unit, Hospital Universitario Virgen Arrixaca, Murcia, Spain (M.N.P., J.R.G.).
ORCID-Profile: Douglas E Cannie, Alexandros Protonotarios, Petros Syrris, Massimiliano Lorenzini, Bianca De Stavola, Anne M Dybro, Thomas M Hey, Maria G Crespo-Leiro, Jose M Larrañaga-Moreira, Fernando de Frutos, Renee Johnson, Thomas A Slater, Lorenzo Monserrat, Luisa Mestroni, Matthew R G Taylor, Gianfranco Sinagra, Zofia Bilinska, Itziar Solla-Ruiz, Roberto Barriales-Villa, Pablo Garcia-Pavia, Juan R Gimeno, Matteo Dal Ferro, Karim Wahbi, Diane Fatkin, Jens Mogensen, Perry M Elliott
Förderung
- NHLBI NIH HHS
Zitieren
APA
Cannie, D. E., Protonotarios, A., Bakalakos, A., Syrris, P., Lorenzini, M., De Stavola, B., Bjerregaard, L., Dybro, A. M., Hey, T. M., Hansen, F. G., Navarro Peñalver, M., Crespo-Leiro, M. G., Larrañaga-Moreira, J. M., de Frutos, F., Johnson, R., Slater, T. A., Monserrat, L., Sengupta, A., Mestroni, L., …, & Elliott, P. M. (2023). Risks of Ventricular Arrhythmia and Heart Failure in Carriers of RBM20 Variants. Circulation: Genomic and Precision Medicine, 16(5), 434-441. https://doi.org/10.1161/circgen.123.004059
Vancouver
Cannie DE, Protonotarios A, Bakalakos A, Syrris P, Lorenzini M, De Stavola B, et al. Risks of Ventricular Arrhythmia and Heart Failure in Carriers of RBM20 Variants. Circulation: Genomic and Precision Medicine. 2023;16(5):434-441. doi:10.1161/circgen.123.004059
BibTeX
@article{Cannie2023,
author = {Cannie, Douglas E and Protonotarios, Alexandros and Bakalakos, Athanasios and Syrris, Petros and Lorenzini, Massimiliano and De Stavola, Bianca and Bjerregaard, Louise and Dybro, Anne M and Hey, Thomas M and Hansen, Frederikke G and Navarro Peñalver, Marina and Crespo-Leiro, Maria G and Larrañaga-Moreira, Jose M and de Frutos, Fernando and Johnson, Renee and Slater, Thomas A and Monserrat, Lorenzo and Sengupta, Anshuman and Mestroni, Luisa and Taylor, Matthew R G and Sinagra, Gianfranco and Bilinska, Zofia and Solla-Ruiz, Itziar and Arana Achaga, Xabier and Barriales-Villa, Roberto and Garcia-Pavia, Pablo and Gimeno, Juan R and Dal Ferro, Matteo and Merlo, Marco and Wahbi, Karim and Fatkin, Diane and Mogensen, Jens and Rasmussen, Torsten B and Elliott, Perry M},
title = {Risks of Ventricular Arrhythmia and Heart Failure in Carriers of RBM20 Variants},
journal = {Circulation: Genomic and Precision Medicine},
year = {2023},
volume = {16},
number = {5},
pages = {434--441},
doi = {10.1161/circgen.123.004059}
}
EUVIMED